Ma ka Pōʻalima, ua hoʻopuka ka European Union drug regulator i kahi 'ʻōlelo aʻoaʻo' e kākoʻo ana i ka hoʻohana pilikia ʻana o ka lāʻau anti-coronavirus hou i hoʻomohala ʻia e ka hui lāʻau lapaʻau multinational ʻAmelika. Merck i ka hui pū ʻana me Ridgeback Biotherapeutics, ʻoiai ʻaʻole ia i ʻae ʻia e nā luna US.
ka Ke Keʻena Laau Lapaʻau ʻEulopa (EMA) ua paipai i ka hoohana pilikia o MerckʻO ka pila no ka mālama ʻana i nā maʻi maʻi maʻi COVID-19 e like me ka piʻi ʻana o nā hihia coronavirus hou ma ka ʻāina ʻEulopa.
Ma kahi'ōlelo, Ema i ʻōlelo ʻia ka lāʻau lapaʻau i kapa ʻia ʻo Lagevrio - ʻike ʻia ʻo molnupiravir a i ʻole MK 4482 - "hiki ke hoʻohana ʻia e mālama i nā pākeke me COVID-19 ʻaʻole koi i ka oxygen supplemental a ke piʻi nei ka pilikia o ka hoʻomohala ʻana i ka COVID-19 koʻikoʻi."
Ua ʻōlelo ʻo EU regulator e hoʻokō koke ʻia ka mālama ʻana ma hope o ka loaʻa ʻana o COVID-19 a i loko o ʻelima mau lā o ka hoʻomaka ʻana o nā hōʻailona. Pono e lawe ʻia ka lāʻau i ʻelua manawa i ka lā no ʻelima mau lā.
ka Ema ua helu ʻia nā hopena ʻaoʻao o ka pila, e like me ka maʻi maʻi a i ʻole ka maʻi maʻi, nausea, dizziness a me ke poʻo. ʻAʻole ʻōlelo ʻia ka lāʻau no nā wahine hāpai.
Ua hoʻolaha mua ka regulator i ka Pōʻalima ua hoʻomaka ʻo ia e loiloi i ka lāʻau lapaʻau ʻo Pfizer Paxlovid no COVID-19 me ka pahuhopu like "e kākoʻo i nā luna aupuni" hiki ke hoʻoholo i kāna hoʻohana mua ʻana ma mua o ka ʻae ʻana i ke kūʻai aku ma muli o ka piʻi ʻana o nā hihia a me nā make ma ʻEulopa.
I kēia lā, ua hoʻolaha ʻo Austria e komo i kahi paʻa paʻa ʻāina hou mai ka Pōʻakahi a hoʻopaʻa ʻia i ka lāʻau lapaʻau, ʻoiai ua ʻōlelo nā luna olakino o Kelemania ua lilo ka ʻāina i "kahi maʻi nui."
Ua noi ʻo Pfizer lāua ʻo Merck i ka ʻae ʻia no kā lākou lāʻau coronavirus mai ka US Food and Drug Administration, akā ʻaʻole maopopo i ka manawa e hāʻawi ʻia ai.
He aha e lawe ʻia mai kēia ʻatikala:
- The regulator announced earlier on Friday that it had begun reviewing Pfizer's medicine Paxlovid for COVID-19 with the same goal “to support national authorities” who may decide on its early use prior to marketing authorization in light of rising cases and deaths in Europe.
- In a statement, EMA said the drug called Lagevrio – also known as molnupiravir or MK 4482 – “can be used to treat adults with COVID-19 who do not require supplemental oxygen and who are at increased risk of developing severe COVID-19.
- The European Medicines Agency (EMA) has recommended the emergency use of Merck's pill for the treatment for clinically vulnerable COVID-19 patients as new coronavirus cases spike across the European continent.
